-
Abstract Number: 1544
Predictors of Response, Adverse Events and Treatment Retention in Ankylosing Spondylitis Patients Treated with Golimumab in a Prospective, Observational Registry
-
Abstract Number: 1545
Ixekizumab Significantly Improves Self-reported Overall Health as Measured by Short-Form-36 in Patients with Active Non-radiographic Axial Spondyloarthritis: 16- and 52-Week Results of a Phase 3 Randomized Trial (COAST-X)
-
Abstract Number: 1546
Effectiveness and Retention Rate of Secukinumab for Psoriatic Arthritis and Axial Spondyloarthritis: Real-life Data from the Italian LORHEN Registry
-
Abstract Number: 1547
Ixekizumab Improves Self-reported Overall Functioning and Health as Measured by the Assessment of SpondyloArthritis International Society Health Index in Patients with Active Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Randomized Trials
-
Abstract Number: 1548
Drug Survival of Secukinumab for Axial Spondyloarthritis in a Real-World Setting Possible Response Factors
-
Abstract Number: 1549
Primary 1-Year Data of Ixekizumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Patients with Radiographic Axial Spondyloarthritis Including Data in Patients Rerandomized from Adalimumab to Ixekizumab
-
Abstract Number: 1550
Ixekizumab Demonstrates Consistent Improvement up to Week 108 in Psoriatic Arthritis Across Individual ACR Components for Patients Naïve to Biologic DMARDs or with Previous Inadequate Response to TNF Inhibitors
-
Abstract Number: 1551
Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration
-
Abstract Number: 1552
Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-naïve Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results Through Week 52 from a Phase-3 Study
-
Abstract Number: 1553
Impact of Peripheral Swollen and Tender Joints at Baseline on Response to Treatment with Secukinumab in Ankylosing Spondylitis
-
Abstract Number: 1554
Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study
-
Abstract Number: 1555
Drug Survival and Safety of Biosimilar CT-P13 versus Reference Infliximab in Patients with Ankylosing Spondylitis: Data from the Korean College of Rheumatology Biologics Registry
-
Abstract Number: 1556
Exposure–Response Modeling of an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, BMS-986165, for Pain Visual Analog Scale Score, in Patients with Psoriasis and Musculoskeletal Symptoms
-
Abstract Number: 1557
Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network
-
Abstract Number: 1558
Should Lupus Podocytopathy Be a Subclass in Class I and Class II Lupus Nephritis?
- « Previous Page
- 1
- …
- 104
- 105
- 106
- 107
- 108
- …
- 198
- Next Page »